Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca receives mixed Seroquel review

AstraZeneca receives mixed Seroquel review

9th April 2009

AstraZeneca has received a mixed review about the safety and efficacy of Seroquel XR.

The Food and Drug Administration’s (FDA’s) Psychopharmacologic Drugs Advisory Committee met to discuss the application of the drug, which was proposed to treat major depressive disorder (MDD) and generalised anxiety disorder (GAD).

It was determined the product was not acceptably safe as a monotherapy for aiding GAD, although it was shown to be effective.

Despite asserting Seroquel XR was not harmless enough for use in broad treatment for MDD, the committee remained undecided about the possible risks it may cause as a monotherapy to the condition in certain instances.

However, it was found to be acceptably safe as adjunctive assistance for MDD, which AstraZenca’s chief medical officer Howard Hutchinson remarked he was pleased with.

“Although the committee recognised the effectiveness of Seroquel XR as monotherapy for MDD and GAD, they had concerns around the long-term safety profile in these new populations,” he commented.

The company will have further discussions with the FDA regarding the application of the drug, Mr Hutchinson concluded.

AstraZeneca employs over 65,000 people, over half (51 per cent) of whom are based in Europe.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.